BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25238284)

  • 41. Histone deacetylase 8 in neuroblastoma tumorigenesis.
    Oehme I; Deubzer HE; Wegener D; Pickert D; Linke JP; Hero B; Kopp-Schneider A; Westermann F; Ulrich SM; von Deimling A; Fischer M; Witt O
    Clin Cancer Res; 2009 Jan; 15(1):91-9. PubMed ID: 19118036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and synthesis of mono and bicyclic tetrapeptides thioester as potent inhibitor of histone deacetylases.
    Hoque MA; Islam MS; Islam MN; Kato T; Nishino N; Ito A; Yoshida M
    Amino Acids; 2014 Oct; 46(10):2435-44. PubMed ID: 25048030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
    Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
    Muthyala R; Shin WS; Xie J; Sham YY
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4320-4. PubMed ID: 26264503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.
    De Vreese R; Van Steen N; Verhaeghe T; Desmet T; Bougarne N; De Bosscher K; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
    Chem Commun (Camb); 2015 Jun; 51(48):9868-71. PubMed ID: 25994553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aceroside VIII is a new natural selective HDAC6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells.
    Ryu HW; Lee DH; Shin DH; Kim SH; Kwon SH
    Planta Med; 2015 Feb; 81(3):222-7. PubMed ID: 25590368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
    Hou X; Du J; Liu R; Zhou Y; Li M; Xu W; Fang H
    J Chem Inf Model; 2015 Apr; 55(4):861-71. PubMed ID: 25757142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
    Rettig I; Koeneke E; Trippel F; Mueller WC; Burhenne J; Kopp-Schneider A; Fabian J; Schober A; Fernekorn U; von Deimling A; Deubzer HE; Milde T; Witt O; Oehme I
    Cell Death Dis; 2015 Feb; 6(2):e1657. PubMed ID: 25695609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Synthesis and activity of some new histone deacetylases inhibitors].
    Cheng YH; Guo YS; Han HZ; Wang N; Zhang GH; Guo ZR; Wu S
    Yao Xue Xue Bao; 2010 Jun; 45(6):735-41. PubMed ID: 20939182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
    Mai A; Massa S; Rotili D; Simeoni S; Ragno R; Botta G; Nebbioso A; Miceli M; Altucci L; Brosch G
    J Med Chem; 2006 Oct; 49(20):6046-56. PubMed ID: 17004718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
    Baud MG; Leiser T; Haus P; Samlal S; Wong AC; Wood RJ; Petrucci V; Gunaratnam M; Hughes SM; Buluwela L; Turlais F; Neidle S; Meyer-Almes FJ; White AJ; Fuchter MJ
    J Med Chem; 2012 Feb; 55(4):1731-50. PubMed ID: 22280363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
    Koppel I; Timmusk T
    Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.